-
USE OF REAL-WORLD EVIDENCE IN PRE-APPROVAL ASSESSMENTS FOR RARE AND ULTRA-RARE DISEASE THERAPIES IN UK, GERMANY, FRANCE, AND THE UNITED STATES
Mar 18, 2026, 21:38 PM -
SAFETY AND EFFECTIVENESS OF EGFR-TKI RECHALLENGE AFTER EGFR-TKI-ASSOCIATED INTERSTITIAL LUNG DISEASE IN ADVANCED NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE COHORT STUDY IN TAIWAN
Mar 18, 2026, 21:38 PM -
BREAST, CERVICAL, PROSTATE, AND COLORECTAL CANCER SCREENING SERVICES UTILIZATION AMONG MEDICARE BENEFICIARIES IN 2019-2022
Mar 18, 2026, 21:38 PM -
ASSESSMENT OF PHARMACEUTICAL CARE SERVICES IN COMMUNITY PHARMACY
Mar 18, 2026, 21:38 PM -
PATIENTS DEFINING WHAT MATTERS: A CROSS-SECTIONAL SURVEY WITH A DISCRETE-CHOICE EXPERIMENT ON UNMET MEDICAL NEED
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF POLYGENIC RISK-GUIDED BREAST CANCER SCREENING WITH AND WITHOUT HBOC TESTING: A DISCRETE-EVENT SIMULATION WITH PROBABILISTIC SENSITIVITY ANALYSIS
Mar 18, 2026, 21:38 PM -
SHORT-TERM COST AND HEALTH OUTCOMES COMPARISON OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT ANALYSIS OF IMPROVED SAFETY AND EFFICACY WITH ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN TRANSPLANT-INELIGIBLE, PREVIOUSLY UNTREATED MCL
Mar 18, 2026, 21:38 PM -
EVALUATING MARGINAL HEALTHCARE EXPENDITURESACROSS DEMOGRAPHIC SUBGROUPS IN DEMENTIA USING BAYESIAN HIERARCHICAL MODELS
Mar 18, 2026, 21:38 PM -
MEASUREMENT OF PREVALENCE AND INCIDENCE IN OPEN CLAIMS DATA: ASSESSMENT OF DIFFERENT METHODOLOGIES
Mar 18, 2026, 21:38 PM -
OPTIMIZING ACCESS TO ACORAMIDIS IN THE UNITED STATES: THE ROLE OF PATIENT ACCESS LIAISONS (PALS) IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Mar 18, 2026, 21:38 PM -
NETNOGRAPHY AS A QUALITATIVE RESEARCH APPROACH TO SUPPORT PATIENT-REPORTED OUTCOME AND PATIENT PREFERENCE RESEARCH IN HEOR
Mar 18, 2026, 21:38 PM -
GLOBAL AND REGIONAL ESTIMATES OF CLINICAL AND ECONOMIC BURDEN OF OSTEOARTHRITIS IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
BEYOND THE HYPE: DO EXISTING VALIDATION METHODS AND GOLD STANDARDS PROVE THE VALUE OF GENERATIVE AI APPLICATIONS FOR HEOR?
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE DRIVERS OF VALUE IN COST-EFFECTIVENESS ANALYSIS
Mar 18, 2026, 21:38 PM -
IDENTIFYING VALUE DRIVERS IN HTA SUBMISSIONS USING GENERATIVE AI: A CASE STUDY OF LONG-ACTING INJECTABLE HIV THERAPY
Mar 18, 2026, 21:38 PM -
BEYOND COST-EFFECTIVENESS: ADAPTING THE ISPOR VALUE FLOWER FOR MULTI-CRITERIA DECISION ANALYSIS IN KAZAKHSTAN
Mar 18, 2026, 21:38 PM -
GLOBAL EPIDEMIOLOGICAL ASSESSMENT OF THE DISEASE BURDEN OF OSTEOARTHRITIS IN 2023
Mar 18, 2026, 21:38 PM -
CLINICAL AND HEALTHCARE FACTORS ASSOCIATED WITH DIABETIC KETOACIDOSIS AT PEDIATRIC TYPE 1 DIABETES DIAGNOSIS IN THE US AND ENGLAND
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS AND GLOBAL REIMBURSEMENT LANDSCAPE FOR DENOSUMAB IN ONCOLOGY
Mar 18, 2026, 21:38 PM
